Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1980 6
1981 6
1982 10
1983 10
1984 28
1985 71
1986 203
1987 454
1988 765
1989 1139
1990 1556
1991 1770
1992 2092
1993 2249
1994 2564
1995 2697
1996 2885
1997 3051
1998 3177
1999 3593
2000 3914
2001 4224
2002 4297
2003 4599
2004 4804
2005 5218
2006 5243
2007 5223
2008 5462
2009 5743
2010 5935
2011 6149
2012 6526
2013 6630
2014 6576
2015 6411
2016 5944
2017 5723
2018 5130
2019 2458
2020 45
Text availability
Article attribute
Article type
Publication date

Search Results

122,686 results
Results by year
Filters applied: . Clear all
Page 1
Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K, et al. Gastroenterology 2019. PMID 31326413 Free article.
It is not clear how inhibitors of cytokines, such as antagonists of tumor necrosis factor (anti-TNF), affect the intestinal microbiome. ...
It is not clear how inhibitors of cytokines, such as antagonists of tumor necrosis factor (anti-TNF), affect the intest …
Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis.
Green LJ, et al. J Drugs Dermatol 2019 - Review. PMID 31424708
Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-17A inhibitors, an IL-12/23 inhibitor, and IL-23 inhibitors. ...
Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients …
Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis.
Bertucci Zoccali M, et al. Dis Colon Rectum 2019. PMID 31596761
Patients exposed to anti-tumor necrosis factor agents or preoperative steroids were significantly more likely to develop pouchitis (anti-tumor necrosis factor: 47.9% vs 36.5%, p = 0.027; steroids: 41.7% vs 23.3%, p = 0.048). However, on multivariable analysis, only anti-tumor necrosis factor therapy was an independent predictor for pouchitis (p = 0.05). ...
Patients exposed to anti-tumor necrosis factor agents or preoperative steroids were significantly more likely to develo …
Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?
Huang Y, et al. Drug Des Devel Ther 2019 - Review. PMID 31308625 Free PMC article.
Objectives: This study evaluated the correlation between tumor necrosis factor alpha inhibitor (TNF-I) and interstitial lung disease (ILD) in rheumatoid arthritis (RA). ...
Objectives: This study evaluated the correlation between tumor necrosis factor alpha inhibitor (TNF-I) and inter …
Tumor necrosis factor-α-308 polymorphism is not associated with Kawasaki disease: A meta-analysis of case-control studies.
Yuan Y, et al. Medicine (Baltimore) 2019. PMID 31261503 Free PMC article.
Some studies have reported that tumor necrosis factor (TNF)-α-308 polymorphism has been associated with KD. However, there have been inconsonant results among different studies. ...Search terms included "Kawasaki disease" or "KD," "tumor necrosis factor-alpha" or "TNF-α," and "polymorphism" or "mutation." ...
Some studies have reported that tumor necrosis factor (TNF)-α-308 polymorphism has been associated with KD. However, th …
Development and Characterization of a Potent Tumor Necrosis Factor-Alpha-Blocking Agent.
Jameei A, et al. Monoclon Antib Immunodiagn Immunother 2019. PMID 31305212 Free PMC article.
Tumor necrosis factor-α (TNFα), one of the major proinflammatory cytokines, plays a key role in an effective immune response. ...
Tumor necrosis factor-α (TNFα), one of the major proinflammatory cytokines, plays a key role in an effective immune res
Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
Bar-Yoseph H, et al. Gastroenterology 2019. PMID 31401142
BACKGROUND & AIMS: Some patients develop anti-drug antibodies (ADAs), which reduce the efficacy of infliximab, a monoclonal antibody against tumor necrosis factor (TNF), in the treatment of immune-mediated diseases, including inflammatory bowel diseases. ...
BACKGROUND & AIMS: Some patients develop anti-drug antibodies (ADAs), which reduce the efficacy of infliximab, a monoclonal antibody aga …
Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.
Bosch-Nicolau P, et al. PLoS Negl Trop Dis 2019 - Clinical Trial. PMID 31469834 Free PMC article.
BACKGROUND: Tumor necrosis factor alpha (TNF-α) blockers are recognized as a risk factor for reactivation of granulomatous infections. ...
BACKGROUND: Tumor necrosis factor alpha (TNF-α) blockers are recognized as a risk factor for reactivation …
Effects of Tumor Necrosis Factor Alpha on the Expression of Programmed Cell Death Factor 5 in Arthritis.
Zhang KS, et al. Orthop Surg 2019. PMID 31282065 Free PMC article.
OBJECTIVE: To investigate the effect of tumor necrosis factor alpha (TNF-α) on the proliferation of fibroblast-like synoviocytes (FLS) and the expression of programmed cell death factor 5 (PDCD5) in an inflammatory microenvironment, for the further understanding of the mechanism of action of TNF-α in promoting the proliferation of synovial cells and the apoptosis of the chondrocytes. ...
OBJECTIVE: To investigate the effect of tumor necrosis factor alpha (TNF-α) on the proliferation of fibroblast-l …
Tumor Necrosis Factor-α Inhibits Bone Marrow Stem Cell Differentiation into Osteoblasts by Downregulating microRNA-34a Expression.
Xin W, et al. Ann Clin Lab Sci 2019. PMID 31308031
Tumor necrosis factor-alpha (TNF-α) (0-10 ng/ml) was added to the cell medium to mimic an inflammatory reaction. Cell apoptosis and proliferation were evaluated by flow cytometry and CyQUANT direct cell proliferation assay respectively. ...
Tumor necrosis factor-alpha (TNF-α) (0-10 ng/ml) was added to the cell medium to mimic an inflammatory reaction.
122,686 results
Jump to page
Feedback